[Clinical evaluation of a new oral cephem, cefdinir, in children].
Cefdinir (CFDN, FK482) was evaluated for its safety, efficacy and pharmacokinetics in 28 children. CFDN was effective in 100% of 22 evaluable cases with respiratory, middle ear, urinary or soft tissue infections. From the clinical response, adverse effects and the pharmacokinetic results, daily dose of 9-18 mg/kg, administered in 3 divided portions is suggested. Increase of dose will be associated with increase of gastrointestinal side effects. The data suggest that CFDN is safe and effective when used in children with infections caused by susceptible bacteria including Staphylococcus aureus.
Meguro
H
H
Department of Pediatrics, School of Medicine, Teikyo University.
Tajima
T
T
Abe
T
T
D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D000077525:Cefdinir; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D013211:Staphylococcus aureus / Q000302:isolation & purification
D002511:Cephalosporins; D000077525:Cefdinir